Easing the Muscle Brake: Trevogrumab Meets Semaglutide

AI-generated image · VitalsDaily

Key Takeaway

Adding trevogrumab, an antibody that blocks the muscle-limiting protein myostatin, to semaglutide reduced lean mass loss by about 3 percentage points over 26 to 52 weeks without slowing fat loss. That amounts to roughly 40% to 47% of the lean tissue lost on semaglutide alone. A second combination that also blocked activin A preserved even more muscle, but it caused frequent muscle spasms, serious adverse events and a 32% dropout rate.

The Scale Says Victory, the Stairs Say Otherwise

Picture a 58-year-old accountant 6 months into semaglutide. She has lost 25 pounds, her blood sugar has settled, and her knees ache less. Yet she mentions something odd at her follow-up visit: carrying groceries up to her apartment feels harder than it used to. Her clinician knows why. When people lose weight quickly, some of what disappears is not fat. Across both bariatric surgery and modern weight-loss drugs, more than 25% of the weight lost typically comes from fat-free mass, which includes skeletal muscle^[2].

Muscle is more than a way to look good on the beach. It is the body’s largest site for disposing of glucose, a major driver…